Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2013 - 2026)

Ocular Therapeutix's Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (changed 0.0% YoY), while the FY2025 annual figure was $14.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was $14.0 million for Q1 2026 at Ocular Therapeutix, roughly flat from $14.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $14.3 million in Q2 2023 to a low of $13.0 million in Q2 2022.
• Historically, Non-Current Deffered Revenue has averaged $13.8 million across 5 years, with a median of $14.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue rose 12.78% in 2022, then slipped 1.78% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $13.4 million in 2022, then gained by 5.59% to $14.1 million in 2023, then fell by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $14.0 million (Q1 2026), $14.0 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.